Skip to Content

Notice

Prospective Grant of Exclusive License: “Analogs of Thalidomide as Potential Angiogenesis Inhibitors”

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

National Institutes of Health, Public Health Service, DHHS.

ACTION:

Notice.

SUMMARY:

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Patent Application S/N 60/271,941, entitled “Analogs of Thalidomide as Potential Angiogenesis Inhibitors,” filed on February 27, 2001, to Celgene Corporation of Warren, NJ.

The prospective exclusive license territory will be worldwide and the field of use may be therapeutics for the treatment of oncology and inflammatory diseases.

DATES:

Only written comments and/or license applications which are received by the National Institutes of Health on or before December 17, 2001 will be considered.

ADDRESSES:

Requests for copies of the patent, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Matthew B. Kiser, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD. 20852-3804. Telephone: (301) 496-7056, X224; Facsimile (301) 402-0220; E-mail kiserm@od.nih.gov.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

U.S. Patent Application S/N 60/271,941 discloses several novel thalidomide analogs that mimic the effects of the “active” thalidomide. The compounds show enhanced potency in the inhibition of angiogenesis without the undesirable effects of administration of thalidomide.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Start Signature

Dated: October 4, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

End Signature End Supplemental Information

[FR Doc. 01-26217 Filed 10-17-01; 8:45 am]

BILLING CODE 4140-01-M